NeoChord key facts
as of Oct 2026- Developer of an artificial chordae delivery system designed to resolve and restore normal mitral valve function.
- NeoChord is valued at approximately $50.0M as of Oct 2026 (last reported valuation).
- It has raised $95.4M across 13 recorded rounds; the latest was Seed Round ($493K) in Feb 2025.
- Notable investors include Deerfield Management, Mayo Clinic Ventures, Baird Capital, Andcor Companies, CHV Capital — 18 tracked in total.
- NeoChord has filed 21 Form Ds with the SEC since 2009, most recently Mar 2025 ($493K sold to 14 investors).
- Status: Privately Held (backing).
NeoChord's last reported valuation, Jun 2015. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch NeoChord: the Monday email on marks, rounds and moves
NeoChord funding rounds
13 roundsWho backs NeoChord
18+Membership and data by Private Market View
NeoChord valuation
NeoChord's last reported valuation was $50 million in Jun 2015. No priced round, secondary trade or fund mark has surfaced since.
How much has NeoChord raised?
NeoChord has raised $95.4 million across 13 recorded rounds since 2012. The largest was a $914,291 seed round in Aug 2024; the most recent was a $493,240 seed round in Feb 2025.
NeoChord has filed 21 Form Ds with the SEC since 2009, most recently in Mar 2025 ($493,240 sold to 14 investors).
NeoChord investors
18 investors are on record for NeoChord, including Deerfield Management, Mayo Clinic Ventures, Baird Capital and Andcor Companies. The seed round in Feb 2025 drew 14 investors.
About NeoChord
Developer of an artificial chordae delivery system designed to resolve and restore normal mitral valve function. The company's system is used for conducting a minimally invasive procedure when the native chordae tendinae have become elongated or ruptured, while the heart is beating and bypasses the need for conducting cardiopulmonary bypass or aortic cross-clamping, enabling surgeons to stop the leakage of blood backward through the mitral valve in patients suffering from mitral regurgitation.
- Sector
- Healthcare
- HQ
- Maple Grove, MN, United States
- Founded
- 2007
- Employees
- 18
- Website
- neochord.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.